Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

aqui-s new zealand limited - isoeugenol - topical solution/suspension - isoeugenol oil-plant extract active 540.0 g/l - anaesthetics/analgesics - salmonids - anaesthetic - local/general | general anaesthetic | immobiliser | local anaesthetic | premedication | sedative | tranquilliser | travel sickness

New Zealand - English - Ministry for Primary Industries

aqui-s new zealand limited - isoeugenol - isoeugenol 540 g/litre - anaesthetic

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 10mg;  ;  ;  ;   - film coated tablet - 10 mg - active: simvastatin 10mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 20mg;  ;  ;  ;   - film coated tablet - 20 mg - active: simvastatin 20mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 40mg;  ;  ;  ;   - film coated tablet - 40 mg - active: simvastatin 40mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 80mg;  ;  ;  ;   - film coated tablet - 80 mg - active: simvastatin 80mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine 15 mg - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. severe glucose-6-phosphate dehydrogenase (g6pd) deficiency (see warnings). pregnant women (see warnings, usage in pregnancy). primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine 15 mg - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. severe glucose-6-phosphate dehydrogenase (g6pd) deficiency (see warnings). pregnant women (see warnings, usage in pregnancy). primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine 15 mg - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.

United States - English - NLM (National Library of Medicine)

bayshore pharmaceuticals, llc - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine 15 mg - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. severe glucose-6-phosphate dehydrogenase (g6pd) deficiency (see warnings). pregnant women (see warnings, usage in pregnancy). primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.